+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Orphan Drug"

From
From
From
From
From
From
Prescription Drugs Market Report 2026 - Product Thumbnail Image

Prescription Drugs Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Rare Disease Pharmaceutical Service Market Report 2026 - Product Thumbnail Image

Rare Disease Pharmaceutical Service Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
From
Preclinical CRO Market Report 2026 - Product Thumbnail Image

Preclinical CRO Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
Primary Ciliary Dyskinesia (PCD) Market Report 2026 - Product Thumbnail Image

Primary Ciliary Dyskinesia (PCD) Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Medical Foods for Orphan Diseases Market Report 2026 - Product Thumbnail Image

Medical Foods for Orphan Diseases Market Report 2026

  • Report
  • January 2026
  • 250 Pages
  • Global
From
From
Oligonucleotides - Competitive Landscape, 2026 - Product Thumbnail Image

Oligonucleotides - Competitive Landscape, 2026

  • Report
  • January 2026
  • 450 Pages
  • Global
From
Transforming Growth Factor Beta Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Transforming Growth Factor Beta Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 150 Pages
  • Global
From
Amyloid Precursor Protein Secretase Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Amyloid Precursor Protein Secretase Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Acute Radiation Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Acute Radiation Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Loading Indicator

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them. The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives. Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more